CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology

Nonsmall Cell Lung Cancer Clinical Trial

Official title:

CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03940846
• Other study ID #: LHist
• Status: Active, not recruiting
• Start date: March 1, 2019
• Est. completion date: January 31, 2021

Study information

• Verified date: April 2019
• Source: Maastricht University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Lung cancer remains the leading cause of cancer related mortality worldwide, with more than 1.5 million related deaths annually. Lung cancer is divided into two main groups: Small Cell Lung Carcinoma (SCLC) and Non-Small Cell Lung Carcinoma (NSCLC), with prevalence of ~20% and 80% respectively. NSCLC is further subdivided into adenocarcinoma (the most common), squamous cell carcinoma (SCC), and large cell carcinoma. Furthermore, each subtype is likely to have specific mutations, which could be targeted for treatment.

Medical imaging and radiomics feature extraction represent a candidate alternative to conventional tissue biopsy, a theory that is investigated in this study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 650
• Est. completion date: January 31, 2021
• Est. primary completion date: October 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Availability of diagnostic non-contrast enhanced CT scan.

• Availability of histologic tumor analysis results

Exclusion Criteria:

-

Related Conditions & MeSH terms

• Adenocarcinoma
• Adenocarcinoma of Lung
• Carcinoma, Non-Small-Cell Lung
• Nonsmall Cell Lung Cancer

Intervention

Diagnostic Test:
• Virtual biopsy
Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.

Locations

Country	Name	City	State
Netherlands	Maastricht University	Maastricht	Limburg

Sponsors (3)

Lead Sponsor	Collaborator
Maastricht University	Radboud University, University of California, San Francisco

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lung histology	Is the tumor under investigation an adenocarcinoma of the lung?	December 2019